Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Full disclosure: GSK’s pledge to open clinical trial data

Soon after GlaxoSmithKline (GSK) pleaded guilty in the US to withholding safety data from regulators, the global healthcare company has been proactive in restoring its image. But will a pledge to make detailed trial data available be enough to appease its critics? Dr Nicola Davies reports.

Go Top